Rapid-release and coat-core formulations of nisoldipine in treatment of hypertension, angina, and heart failure

Nisoldipine, a dihydropyridine calcium antagonist, has greater vascular selectivity than other Calcium Channel antagonists and does not depress the intact myocardium in vivo. It should be taken on an empty stomach. Both rapid-release and coat-core formulations are available for clinical use, but only the coat-core formulation extends antihypertensive, antiischemic, and antianginal effects throughout the dosing interval when given once daily. The coat-core formulation in daily doses of 10 to 40 mg does not cause the proischemic effects reported with the rapid-release formulation. When given as monotherapy, the coat-core formulation is highly effective in lowering blood pressure to a similar extent as other long-acting Calcium Channel blockers, diuretics, beta-blockers, or angiotensin-converting Enzyme (ACE) inhibitors. The antihypertensive effects are potentiated when the coat-core formulation of nisoldipine is given in combination with lisinopril. In patients with stable angina pectoris nisoldipine coat-core increases exercise duration, reduces anginal frequency and myocardial ischemia, and is effective as monotherapy or in combination with a beta-blockers. In monotherapy the drug is as effective as other long-acting Calcium Channel blockers or a beta-blocker. The effects of nisoldipine coat-core in patients with heart failure are unclear at present.